within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA58_EfgartigimodAlfa;
model EfgartigimodAlfa 
   extends Pharmacolibrary.Drugs.ATC.L.L04AA58;

  annotation(Documentation(
    info ="<html><body><p>Efgartigimod alfa is a human IgG1-derived Fc fragment designed to bind to the neonatal Fc receptor (FcRn), resulting in a reduction of circulating IgG levels. It is approved for the treatment of generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as reported in healthy adult subjects after intravenous infusion.</p><h4>References</h4><ol><li><p>Jing, S, et al., &amp; Pu, X (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants. <i>Drugs in R&amp;D</i> 24(4) 505â€“515. DOI:<a href=&quot;https://doi.org/10.1007/s40268-024-00490-6&quot;>10.1007/s40268-024-00490-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39368043/&quot;>https://pubmed.ncbi.nlm.nih.gov/39368043</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end EfgartigimodAlfa;
